Sudhir Kandarth brings more than 15 years experience to build Indian business
MUMBAI, INDIA — 23 March, 2015 — Veeva Systems, a leading provider of industry cloud solutions to life sciences, today announced the appointment of Sudhir Kandarth as country general manager of India, bringing more than 15 years of life sciences experience to this swiftly growing division. Reporting directly to General Manager for Asia Pacific Alex Paris, Sudhir will be responsible for supporting the ongoing success of the company’s customers in India and expanding Veeva’s presence in the country.
“We are excited to welcome Sudhir to lead the Veeva team in India,” Mr. Paris said, “With the Indian pharmaceutical market expected to grow to USD 55 Billion by 2020 according to McKinsey and Company[i], Veeva’s goal is to serve as the industry’s most strategic partner in a key emerging market.”
Over the next several months, Sudhir will focus on building a team of Veeva experts based in India. “The strengthening of Veeva’s presence in India is a mark of our strong commitment to the region,” said Sudhir. “We are dedicated to working closely with local customers and serving the unique needs of this market.”
Prior to joining Veeva, Sudhir served as sales manager at Oracle Health Sciences, and also held roles at IBM, SAS Inc. and Dr.Reddy’s. Sudhir’s experience spans across the commercial and R&D parts of the pharmaceutical value chain, from launching one of the earliest sales force automation projects in India and more recently enabling the growing clinical IT R&D requirements of the Indian pharmaceutical industry,
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 275 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including statements regarding Veeva’s future plans with respect to India demand for Veeva’s solutions in India and general business conditions. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2014, which is available on the company’s website at www.veeva.com under the Investors section and on the SEC’s website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
###
Contact
Jacqueline Davis
Veeva Australia Pty Ltd
61 411 284 900
jacqueline.davis@veeva.com
[i] McKinsey and Co, Inc, “India Pharma 2020: Propelling access and acceptance, realising true potential”, 2010, http://www.mckinsey.com/-/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/778886_India_Pharma_2020_Propelling_Access_and_Acceptance_Realising_True_Potential.ashx